Kamada (KMDA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

KMDA · Stock Price

USD 8.26+1.38 (+20.06%)

Market Cap: $483.3M

Historical price data

Market Cap: $483.3MPipeline: 16 drugs (6 Phase 3)Patents: 7Founded: 1990Employees: 500-1000HQ: Rehovot, Israel

Sector Ranking#129 in Biologics / Biosimilars #49 in Rare & Orphan Diseases

Overview

Kamada is a profitable, vertically integrated biopharmaceutical company with a mission to provide high-quality therapeutics for rare and serious conditions. The company has achieved record financial performance, driven by its commercial plasma-derived products, a robust development pipeline led by an inhaled Alpha-1 Antitrypsin candidate, and a strategic CDMO business. Its strategy is built on a three-pillar model: commercial execution, innovative R&D, and leveraging its industry-leading manufacturing capabilities for organic and partnership-driven growth.

Rare DiseasesPulmonologyImmunologyTransplant Medicine

Technology Platform

Proprietary platform for chromatographic purification and viral inactivation of plasma-derived proteins, coupled with a specialized inhaled delivery technology for pulmonary administration of therapeutics like Alpha-1 Antitrypsin.

Pipeline

16

16 drugs in pipeline6 in Phase 3

Drug	Indication	Stage
Cytogam	Cytomegalovirus (CMV) Infection	Approved
Cytomegalovirus Immune Globulin Intravenous (Human) monthly ...	Cytomegalovirus	Approved
KamRAB - HRIG	Rabies	Phase 3
Alpha 1-Antitrypsin + Placebo	Alpha 1-Antitrypsin Deficiency	Phase 3
Active rabies vaccine (US-FDA approved)	Rabies	Phase 2/3

Opportunities

The primary opportunity is the potential approval and commercialization of inhaled AAT, which could capture significant market share in the ~$1.5B AATD therapy market by offering superior convenience.

Additional opportunities include expanding AAT into new multi-billion dollar indications like GvHD and Type 1 Diabetes, and growing the high-margin CDMO business by leveraging unique protein manufacturing expertise.

Risk Factors

The key risk is clinical failure or delay of the Phase 3 inhaled AAT trial, on which much of the company's growth valuation depends.

Additional risks include regulatory hurdles, commercial execution challenges against established IV competitors, and exposure to plasma supply cost volatility.

Competitive Landscape

In AATD, Kamada faces competition from established IV products (CSL, Grifols) and other companies developing next-generation delivery methods. Its vertical integration provides a cost and supply chain advantage. In the CDMO space, it competes with large players by offering specialized expertise in complex protein purification for niche biologics.